|ICU Medical, Inc.|
951 Calle Amanecer
United States - Map
ICU Medical, Inc. develops, manufactures, and sells medical devices used in infusion therapy, oncology, and critical care applications. It operates in three segments: Infusion Therapy, Critical Care, and Oncology. The companys product line includes needlefree infusion connectors, custom infusion systems, catheters and hemodynamic monitoring systems, closed system transfer devices, and automated compounders for handling hazardous drugs. Its products enhance patient outcomes by preventing bloodstream infections, and protecting healthcare workers and patients from exposure to infectious diseases or hazardous drugs. The company offers I.V. therapy lines consisting of a tube running from a bottle or plastic bag containing an I.V. solution to a catheter inserted in a patients vein for use in hospitals and ambulatory clinics; and Clave product, a needlefree infusion connection device, which is used with conventional peripheral or central vascular access systems for venous and arterial applications. It also provides critical care products that monitor vital signs and specific physiological functions of key organ systems, including disposable pressure-sensing devices, blood sampling systems, minimally invasive monitoring sensors, catheters, and angiography kits for various purposes. In addition, the company provides a line of oncology products, including ChemoLock and ChemoClave closed system transfer device and components, including Genie closed vial access device and Spiros closed male luer; custom preparation and administration sets and accessories; and Diana hazardous drug compounding system. Further, it offers Tego needlefree hemodialysis connectors and Lopez enteral valves. ICU Medical, Inc. sells its products to medical product manufacturers, independent distributors, and directly to end users. The company was founded in 1984 and is headquartered in San Clemente, California.
|ICU Medical, Inc.’s ISS Governance QuickScore as of Aug 1, 2014 is 10. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 10; Compensation: 6.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Scott E. Lamb ,
Chief Financial Officer, Treasurer and Sec.
|Mr. Steven C. Riggs ,
VP of Operations
|Ms. Alison D. Burcar ,
VP of Product Devel.
|Mr. Vivek Jain ,
Chairman and Chief Exec. Officer
| Kevin J. McGrody ,
Principal Accounting Officer and Controller
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|